Because the majority of non-NF-2 meningioma driver mutations such as SMO, AKT1, SMARCB1, and TRAF7 normally occur mutually exclusive of NF-2, the expected rate of these mutations would be lower in high-grade tumor cohorts. This evidence concerns the gene NF2 and neoplasm.